Abstract | AIM: METHODS: Immunofluorescence staining of γH2AX or 53BP1 was used to determine the effect of palbociclib on double-strand break ( DSB) repair. Clonogenic assays, sphere formation and cell death ELISA were performed to study the sensitising effect of palbociclib on radiation-induced cytotoxicity. Signal alteration in DSB repair pathways was examined by Western blot analysis. Finally, we evaluated the in vivo anti- cancer activity and the associated molecular events of the combination therapy in a preclinical HCC xenograft model. RESULTS: CONCLUSION: Our findings provide a novel combination strategy against liver cancer cells. Clinical trials using palbociclib as an adjuvant in RT are warranted.
|
Authors | Chao-Yuan Huang, Feng-Shu Hsieh, Cheng-Yi Wang, Li-Ju Chen, Shih-Shin Chang, Ming-Hsien Tsai, Man-Hsin Hung, Chiung-Wen Kuo, Chi-Ting Shih, Tzu-I Chao, Kuen-Feng Chen |
Journal | European journal of cancer (Oxford, England : 1990)
(Eur J Cancer)
Vol. 102
Pg. 10-22
(Oct 2018)
ISSN: 1879-0852 [Electronic] England |
PMID | 30103095
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2018 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- H2AX protein, human
- Histones
- Piperazines
- Protein Kinase Inhibitors
- Pyridines
- Radiation-Sensitizing Agents
- TP53BP1 protein, human
- Tumor Suppressor p53-Binding Protein 1
- ATM protein, human
- Ataxia Telangiectasia Mutated Proteins
- palbociclib
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology)
- Ataxia Telangiectasia Mutated Proteins
(antagonists & inhibitors, metabolism)
- Bile Duct Neoplasms
(enzymology, genetics, pathology, therapy)
- Carcinoma, Hepatocellular
(enzymology, genetics, pathology, therapy)
- Cell Line, Tumor
- Chemoradiotherapy
- Cholangiocarcinoma
(enzymology, genetics, pathology, therapy)
- DNA Breaks, Double-Stranded
- DNA Repair
(drug effects)
- Histones
(metabolism)
- Humans
- Kinetics
- Liver Neoplasms
(enzymology, genetics, pathology, therapy)
- Male
- Mice, Nude
- Piperazines
(pharmacology)
- Protein Kinase Inhibitors
(pharmacology)
- Pyridines
(pharmacology)
- Radiation Tolerance
- Radiation-Sensitizing Agents
(pharmacology)
- Tumor Suppressor p53-Binding Protein 1
(metabolism)
- Xenograft Model Antitumor Assays
|